ArticleCureus2024
Diagnostic Accuracy of Cancer Antigen 15-3 as a Seromarker Among Recurrent Breast Carcinoma in Bangladesh.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of recurrent breast carcinoma is crucial for patient treatment. The present study aimed to assess the diagnostic accuracy of cancer antigen 15-3 (CA 15-3) as a sero-marker among recurrent breast carcinoma patients.
methodsThis prospective observational study evaluated the serum CA 15-3 among women (age ≥18 years) with recurrent breast carcinoma. The CA 15-3 was measured by the enzyme-linked immunosorbent assay (ELISA), and concentrations were stratified using a cut-off value of 30 U/mL. The receiver operating characteristic (ROC) curve observed that the sensitivity and specificity of the CA 15-3 cut-off value and the area under the AUROC curve demonstrate the goodness-of-fit of the prediction model.
resultsA total of 50 patients were recruited, with a mean age of 48.4 ±9.7years. The majority (n=28, 56.0%) of patients were 41 to 50 years old. Further, a total of 42 (84%) patients had high serum levels of CA 15-3, with a mean value of 72.7±9.5 U/mL. At the cut-off level of 30 U/mL, the ROC curve demonstrated sensitivity, specificity, positive predictive value, and negative predictive value of 95.7%, 69.4%, 84.1%, and 72.8%, respectively, to diagnose recurrent breast carcinoma. Nonetheless, the area under the ROC (AUROC) curve was 0.712, indicating a satisfactory fit for the prediction model.
conclusionWe found that CA 15-3 level ≥30 U/mL is highly sensitive and specific as a seromarker for detecting recurrent breast cancer among the Bangladeshi population. We recommend routinely monitoring breast cancer survivors using CA 15-3 biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.